NCT06981741View on ClinicalTrials.gov

Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Cartilage Damage
Interventions
BIOLOGICAL

BP CC 001

10-20 x 10\^6 UC-MSC in 1 ml suspension, applied to a collagen carrier structure (Chondro-Gide®)

Trial Locations (7)

13589

Evangelisches Waldkrankenhaus Spandau, Berlin

46535

GFO Kliniken Niederrhein, St. Vinzenz Hospital Dinslaken, Dinslaken

48268

Maria-Josef-Hospital Greven, Klinik für Unfallchirurgie und Orthopädie, Greven

56626

St. Nikolaus Stifts-Hospital, Andernach

96049

Sozialstiftung Bamberg Klinikum am Bruderwald, Klinik für Orthopädie und Unfallchirurgie, Bamberg

04600

Klinikum Altenburger Land, Klinik für Orthopädie und Unfallchirurgie, Altenburg

01307

UniversitätsCentrum für Orthopädie, Unfall- & Plastische Chirurgie, Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden

All Listed Sponsors
collaborator

KKS Netzwerk

NETWORK

collaborator

Fraunhofer Institute for Cell Therapy and Immunology IZI

UNKNOWN

collaborator

Polski Bank Komorek Macierzystych JSC (PBKM)

INDUSTRY

lead

BIONCaRT GmbH

INDUSTRY

NCT06981741 - Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint | Biotech Hunter | Biotech Hunter